RAPP (rapportrx.com) יחס שווי שוק לשווי בספרים
Rapport Therapeutics, Inc. (RAPP) is a biotech developer creating high-precision treatments for pain and epilepsy by targeting brain receptors without side effects. This market price chart, with a value of 3.11, clearly illustrates the asset's quotes. Business revenues will be based on the sale of targeted drugs to patients and insurance funds. The company is currently completing key tests of breakthrough small molecules for the therapy of focal epilepsy.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_RAPP_-_Rapport-Therapeutics-Inc._-_Market-Capitalization-to-Net-Assets "RAPP יחס שווי שוק לערך בספרים Rapport Corp (08.06.2024 - 28.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור Rapport Therapeutics Inc (RAPP)
The prospects of Rapport Therapeutics, Inc. (RAPP) depend on the success of clinical trials for CNS drugs and patent protection, making intellectual capital a key asset. The price-to-book value ratio trend reflects the market's revaluation of these intangible advantages relative to net assets, showing the premium investors are willing to pay for the business's future growth potential beyond its current book value.